NCT05312697Phase 2Terminated

Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta

Study sponsor: Ultragenyx Pharmaceutical Inc · RARE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-07-07Actual
Enrollment · participants2Actual
Source updated2025-07-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.